GlassScriptPhysician profile
Ellen P Barnes
NPI 1609259977
$2,268.06
in general payments reported to CMS, 2019-2025
28 companies · $808 in 2025
The $808 reported for 2025 was more than what 80% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $184 · 2022: $308 · 2023: $624 · 2024: $344 · 2025: $808.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,588 · Education: $188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,587.97 |
| Education | $188.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $734.60 | 2023-2025 | Breztri, Fasenra, Airsupra |
| Lilly USA, LLC | $224.59 | 2022-2025 | Mounjaro, Jardiance, Emgality |
| Abbvie INC. | $205.73 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $120.61 | 2023-2025 | |
| Mallinckrodt Hospital Products INC. | $115.68 | 2022 | |
| Sanofi-Aventis U.S. LLC | $109.44 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $106.97 | 2024-2025 | Dupixent |
| Novo Nordisk INC | $92.99 | 2021-2025 | Ozempic, Rybelsus |
| Genzyme Corporation | $71.83 | 2021-2025 | |
| Verona Pharma, INC. | $52.76 | 2025 | Ohtuvayre |
| Takeda Pharmaceuticals U.S.A., INC. | $50.07 | 2022 | |
| Pfizer INC. | $49.48 | 2021-2025 | |
| Phathom Pharmaceuticals, INC. | $44.19 | 2025 | Voquezna |
| Amgen INC. | $34.68 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.17 | 2022-2024 | Jardiance |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $25.97 | 2021-2022 | |
| Kerecis Limited | $25.84 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Merz Pharmaceuticals, LLC | $20.50 | 2025 | Xeomin |
| Kyowa Kirin, INC. | $19.62 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $18.14 | 2025 | Austedo Xr |
| Ultragenyx Pharmaceutical INC. | $18.07 | 2023 | |
| Philips North America LLC | $14.89 | 2023 | |
| Idorsia Pharmaceuticals US INC | $14.21 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $13.81 | 2025 | Camzyos |
| Kci USA, INC. | $13.57 | 2021 | |
| Grifols USA, LLC | $13.21 | 2023 | Gamunex-C |
| Janssen Pharmaceuticals, INC | $12.31 | 2021 | |
| Mdd US Operations, LLC | $12.13 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ellen Barnes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.